UW’s Promising Therapeutic for Celiac Disease featured in “Chemical and Engineering News”

Celiac disease is one of several diseases involving intolerance to dietary gluten protein that causes serious health problems. UW researcher Ingrid Swanson Pultz and Justin Siegel of the University of California at Davis are developing a promising therapeutic for celiac disease and gluten intolerance that was invented using advanced computational enzyme design. The result, KumaMax, breaks down gluten under the harsh conditions of the human stomach in less than an hour. This enzyme has tremendous potential as a clinical therapeutic.

Celiac disease is estimated to afflict approximately 1% of the population, including over 3 million Americans. The market for celiac disease is estimated to be greater than $512M in 2017 and $664M in 2019. An additional 9% of the population is thought to experience other negative health effects upon ingesting gluten.

Read the feature in Chemical and Engineering News.